Instituto Grifols, S.A.
Clinical trials sponsored by Instituto Grifols, S.A., explained in plain language.
Spanish subsidiary of a global plasma-derived medicines company, focusing on research and development.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Blood filtering treatment tested for sudden liver failure
Disease control Stopped earlyThis study tested a blood filtering procedure called plasma exchange using a 5% albumin solution in people with acute-on-chronic liver failure (ACLF), a sudden worsening of chronic liver disease. The trial enrolled 274 high-risk patients across the US, Canada, and Europe, compari…
Phase 3 • Sponsor: Instituto Grifols, S.A. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Polio Survivors' hope dashed: trial of immune treatment halted early
Disease control Stopped earlyThis study tested a blood product called immune globulin (Flebogamma) in 191 people with post-polio syndrome, a condition causing new muscle weakness years after polio. The goal was to see if it could improve walking distance and reduce pain. The trial was terminated early, so we…
Phase 2/3 • Sponsor: Instituto Grifols, S.A. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC